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Abstract: The aim of our research work was to develop dermally applicable, semisolid film-forming
systems (FFSs) containing silicones, which form a film on the skin in situ, with suitable mechanical
properties for skin application. FFSs were developed and investigated by means of the Quality by
Design (QbD) methodology. With this QbD approach, the initial risk assessment defines the critical
quality attributes (CQAs), the critical material attributes (CMAs) and the critical process parameters
(CPPs) to ensure the required quality. Different semisolid systems were formed with or without
silicones. During the initial risk assessment, three CQAs, namely skin adhesion, film flexibility and
burst strength, were found to be critical attributes, while film appearance, film integrity and the
drying time of the semisolid system, were found to be medium attributes. These parameters were
investigated. The initial risk assessment also showed that there are three high CMAs: the type
of silicones, film-forming excipients, drying excipients, and that there was one medium CMA:
viscosity-enhancing excipients. Based on our results, the silicone content had a great effect on the
film-forming systems. Different silicones affected the mechanical properties of the films in varying
ways, decreased the drying time and showed promising results regarding the drying mechanism.
Keywords: in situ dermal film; film forming system; quality by design; silicones
1. Introduction
The dermal route of drugs has high potential in the health care system. One of the most important
advantages of this route is the possibility to achieve a high concentration of the drug on the application
site, which is promising for local anesthesia, arthritis or acne treatment. It gives good patient compliance,
as it is a comfortable and painless administration route.
On the other hand, it is a great challenge to provide penetration through the skin because this
organ is the first protection line against external impacts [1]. The skin has three functional layers:
the epidermis, the dermis and the subcutis [2]. The outermost layer of the epidermis is the stratum
corneum (SC), which is the most important layer to protect the skin. It has many functions, such as, to
inhibit excessive water loss to ensure optimal skin hydration, and to defend the body from microbial
pathogens, such as bacteria, and from various toxins as well [3].
The amount of active ingredients penetrating into the SC depends upon the properties of the drug,
the physiological parameters of the skin, and the applied drug delivery system. From the aspects of
pharmaceutical technology, one of the main tasks is to ensure and improve the penetration of the active
ingredients into the desired skin layer. There are some innovative dermal drug delivery systems, such
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as the in situ film-forming system, which can be a promising choice to achieve higher drug penetration
through the skin with good patient adherence.
In situ film-forming systems (FFSs) are new alternative, semisolid drug delivery systems [4,5]
that produce a film in situ, after application onto the skin surface. They are composed of volatile and
non-volatile components. After the application, the volatile component(s) evaporate(s), leaving an in
situ film upon the skin. The non-volatile components make a matrix, encompass the drug and provide
the transport through the stratum corneum [6]. With the evaporation of the volatile components,
the drug concentration increases on the skin surface, creating a supersaturated system. Supersaturation
increases drug penetration through the skin, without modifying the skin barrier [6]. Compared with
transdermal patches and conventional semisolid dosage forms, FFSs possess all their advantages. FFS
preparations can be retained for a longer time than conventional semisolid preparations, thanks to
their good adhesion to the skin. They are almost invisible, dry fast, and after drying they have a
non-sticky, non-greasy feeling, and due to their flexibility they are easily removable [7]. FFSs could be
a promising choice for dermal application, for example in acne therapy or local anesthesia to improve
the patient’s adherence.
When designing a film-forming system, it is important to choose appropriate components to ensure
the formation of an optimal film product. The critical point of the compositions is the appropriate
volatile and non-volatile components and their features. Film-forming agents, drying excipients and
viscosity-enhancing agents are essential components to get a film product [8].
Silicones are popular ingredients in the pharmaceutical and cosmetics industries. In the
pharmaceutical application, the most commonly used silicones are cyclomethicone and
dimethicone [9,10]. In the case of in situ film formation, silicones can influence the properties of
the film, and thus skin penetration, too. Cyclomethicone is a volatile silicone which can influence the
drying properties of FFSs. Dimethicone is a non-volatile silicone that can improve the quality and the
performance of dermal preparations, as it gives a “silky touch” feeling, has a good protective effect and
also softens the skin. They are safe to use, provide an aesthetic appearance for the product and are
resistant against water washing [11]. The silicone molecules can make a semi-occlusive formulation,
which can influence the penetration of active ingredients into the SC.
In the development of new pharmaceutical formulations, appropriate quality can be ensured
with the Quality by Design (QbD) concept [12]. It is a holistic, systematic approach that begins with
predefined targets, and emphasizes product and process understanding, as well as process control,
based upon quality risk management [12–14]. The QbD concept involves identifying the quality target
product profile (QTPP), the critical material attributes (CMAs), the critical process parameters (CPPs)
and the critical quality attributes (CQAs) of a product at the beginning of its development [15]. These
factors are screened with risk assessment within those quality tools. Several quality tools can be found
in the International Council for Harmonization (ICH) guideline Q9 (e.g., Ishikawa diagram, Pareto
analysis, risk estimate matrix (REM), etc.). The critical parameters of the formulation are defined based
upon risk assessment [16,17]. During in situ FFS development, the QbD method is a novel approach
which improves the product quality by understanding formulation parameters.
The aim of our research work was to develop a dermally applicable, silicone-containing semisolid
in situ FFS on the basis of the QbD approach. Our study focuses on the determination of critical quality
parameters, which have the highest influence on the formulation, using QbD tools. The most critical
parameters are required to be examined, and the effect of different silicones on these parameters must
be compared.
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2. Materials and Methods
2.1. Materials
Poly(vinyl alcohol) (PVA) (87%–90% hydrolyzed, Mw = 30,000–70,000 g/mol) was from
Sigma-Aldrich (Budapest, Hungary). Ethanol (96 per centum, Ph. Eur. 9.) was obtained from
Molar Chemicals Ltd. (Budapest, Hungary). Xantural® 180 Xanthan Gum was provided by CP Kelco A
Huber Company (Atlanta, GA, USA). ST-Cyclomethicone 5-NF, Dimethiconol Blend 20, ST Elastomer
10 and 7-3101 Elastomer Blend HIP Emulsion were kindly provided by Dow Corning (Midland, MI,
USA). Purified and deionized water was used (Milli-Q system, Millipore, Milford, MA, USA).
Methyl parahydroxybenzoate (Ph. Eur. 9.) was supplied by Molar Chemicals Ltd. (Budapest,
Hungary). Salvequick® sticking plaster was obtained from Orkla Care AB (Solna, Sweden). PVA-based
artificial skin was from Tattoo machine Webshop (© 2018, Mátészalka, Hungary).
2.2. Quality by Design Methodology
2.2.1. Definition of TPP and QTPP
The first step of development by the Quality by Design (QbD) approach is to define the Target
Product Profile (TPP), such as the route of administration, dosage form and strength, etc. [18]. In order
to reach the quality properties, we need to summarize the quality target product profile (QTPP).
The QTPP includes quality, efficiency and safety, with the consideration of appearance, physical
properties, homogeneity, etc. depending on the dosage form [18].
2.2.2. Definition of CQA, CMA, CPP
When QTPPs have been defined, the second step of the QbD-based development is to determine
the critical quality attributes (CQAs) which have to be ensured to achieve the required final quality of
the product. The CQAs are derived from the QTPP. The CQAs are physical, chemical or microbiological
properties within an appropriate range to ensure the desired product quality. The CQAs may include
pH, homogeneity, viscosity, adhesion properties, etc., depending on the dosage form, such as semisolid
systems. The next step of the QbD-based development is to define the critical material attributes
(CMAs) and critical process parameters (CPPs) that may influence product CQAs. These factors
include properties of the excipients (e.g., polymer and surfactant), properties of the drug and process
parameters (e.g., homogenization time and temperature) [19–21].
2.2.3. Risk Assessment: Quality Tools
Risk assessment is the base of the QbD concept. Risk assessment involves the use of quality
tools, which help improve the quality of products and processes. In our research, risk assessment
started with one popular basic quality tools method called the Ishikawa diagram. This method is
one of the “cause and effect” diagram types, which helps to collect the effect and the possible causes
influencing quality. The essence of the method is that the causes are ordered in an organized system.
Not only the major causes, but also the more detailed factors, are identified [22]. The Ishikawa diagram
summarizes materials and process parameters to help the development of a semisolid film-forming
system (Figure 1).
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Figure 1. Ishikawa diagram of material attributes and process parameters of film-forming
systems (FFSs).
Critical parameters were determined by Pareto analysis, also called ABC analysis [21]. A-items
are the high-risk parameters, B-items are the medium-risk parameters and C-items are the low-risk
parameters [17]. A risk estimate matrix (REM) was used during risk assessment to define the level of
the risk parameters. The LeanQbD™ software (QbD Works LLC, Fremont, CA, USA) was used for the
risk assessment.
2.3. Pr paration of FFSs
Three different kinds of FFSs were prepared. The composition of the different formulations
can be found in Table 1. One of the formulations did not contain silicones (F1), but the other two
FFSs contained different volatile and non-volatile silicone components (F2, F3). The function of
volatile silicone (ST-Cyclomethicone 5-NF) was to ensure the fast drying of the film. The other type
of silicones was that type of non-volatile silicones, such as Dimethiconol Blend 20, ST-Elastomer 10
and 7-3101 Elastomer Blend HIP Emulsion. They have different functions in the formulations, they
are film-forming excipients, and furthermore can influence the appearance of the film, give a “silky
touch” feeling, have a good protective effect on the skin, and soften it. F2 included 25% of silicones,
while F3 contained 50% of silicones in the composition. The amount of volatile silicone was the same
in both formulations. PVA and Xanthan gum are film-forming and viscosity-increasing excipients in
the formulations. Finally, the ethanol content helps the film to dry and ensures the required drying
time together with volatile silicone [7,23].
During the preparation, PVA was dissolved in purified water at 80 ◦C under continuous mixing.
Ethanol 96% was added at room temperature. After that, Xanthan gum was added to provide optimal
consistency. Finally, the silicones were added one by one slowly and mixed with a high shear mixer.
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Table 1. Composition of different formulations.
Composition Function of the Excipient F1 F2 F3
Purified water with methyl parahydroxybenzoate Solvent with preservatives + + +
Ethanol 96% Drying + + +
PVA Film forming,Viscosity enhancing + + +
Xanthan gum Film forming,Viscosity enhancing + + -
Dimethiconol Blend 20 Film forming - + -
ST-Elastomer 10 Film forming - + -
7-3101 Elastomer Blend HIP Emulsion Film forming - - +
ST-Cyclometicone 5NF Drying excipient - + +
2.4. Investigation of the Mechanical Parameters of the Films
The mechanical properties of the films were investigated with a TA.XT plus Texture Analyzer
(Stable Micro Systems Ltd., Vienna Court, Lammas Road, Godalming, Surrey, UK. GU7 1YL) [24].
The instrument has different accessories, and depending on the formulation, different attributes of
the film can be characterized. Film Support Rig and 90 Degree Peel Rig equipment were used during
the experiment.
2.4.1. Measurement of Skin Adhesion
Skin adhesion studies investigate the force needed to separate the film from the skin surface.
For these measurements, a film with a surface of 10 × 2 cm was used. 90 Degree Peel Rig equipment
was used to measure the initial and the mean peeling force which was needed to separate the film from
the artificial skin [25]. The test speed was 5 mm/s and the distance was 50 mm. During the evaluation,
the mean peel force was averaged from 10 mm to 45 mm.
2.4.2. Measurement of Film Flexibility
The flexibility of the film can have an effect on skin feeling (and thus on patient adherence), and it
can help the formulation to remain on the skin surface. It was analyzed by the resilience value and the
mean force at the target distance. The free film was also placed into the film supporting rig [26]. A
compression test mode was used where the test speed, force and target distance were 0.5 mm/s, 100 g
and 1 mm, respectively. Force at target distance (N) and resilience (%) were detected. The detected
curve had a maximum peak when the test reached the target distance. Resilience is the ratio of the
areas after and before the maximum peak. The measured film resilience values were compared with
the resilience of the heat-separated human epidermis. The preparation of this heat-separated epidermis
was based upon a procedure reported by Kligman and Christophers [27].
2.4.3. Measurement of Film Burst Strength
Burst strength is the force needed to rupture the film from the skin surface, while distance at burst
is the maximum distance of the deformation before the rupture. Circles with a diameter of 22 cm were
cut from the peeled free film and placed into the film support rig [26]. A compression test mode was
used where the test speed, force and distance were 1 mm/sec, 100 g and 10 mm, respectively. Burst
strength (N) and distance at burst (mm) of the films were measured.
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2.5. Investigation of Film Integrity and Appeariance
For the measurement, 0.2 g of each formulation was deposited on a 3 × 3 cm surface of
the PVA-based artificial skin, left there until it was completely dry, and then the properties were
investigated visually.
2.6. Investigation of the Drying Time of FFSs
Drying time is an important parameter of the FFSs. If the preparations need less time to dry,
patient compliance is better. After drying, a compact flexible film layer is formed, which is not greasy
and does not smear on the skin. During the experiment, the preparation was placed onto the PVA-based
artificial skin. After the top of the layer seemed dry, a microscope slide was placed on the top of the
formulation without pressure. If the formulation did not leave a mark on the slide, it meant that the
film was dry. This was the drying time of the film. If the film was not dry, the test was repeated until
we got a dry film [28].
The drying mechanism of the different FFSs was measured by DSC (Mettler-Toledo DSC 821e,
Columbus, OH, USA). The measurement was performed in an argon and nitrogen atmosphere.
15–20 mg of samples was laid in 40-µL aluminum pans and small holes were made on the tops.
The temperature was increased from 25 ◦C to 150 ◦C by 10 ◦C per minute.
2.7. Statistical Analysis
The one-way analysis of variance (ANOVA—Dunnett) with Prism 8 for Windows software
(GraphPad Software Inc., La Jolla, CA, USA) was used to analyze the results statistically. The differences
were significant if p < 0.0001**** versus the control [18].
3. Results & Discussion
3.1. Determination of QTPP and CQAs for In Situ FFSs
The QTPP of the FFS-containing silicones includes the route of administration, dosage form, site
of activity, appearance of drug delivery system, stability, silicone content, packaging material type
and mechanical properties of the film for skin application. The properties of the semisolid system and
the formed film depend on the type and attributes of the applied excipients. The silicone content can
influence the properties of the FFS, such as the mechanical and drying properties, and the appearance
of the preparation. The CQAs are defined from the QTPPs. The CQAs were determined with the
consideration of the characteristics of the semisolid system and the formed film, too. On the one hand,
the properties of the semisolid system include physical properties, viscosity, homogeneity, pH, skin
feeling, drying time, physical, chemical and microbiological stability. On the other hand, the formed
film has properties like film appearance, burst strength, skin adhesion, film flexibility and integrity.
Tables 2 and 3 show the QTPP and CQA parameters with their targets and their justifications.
Table 2. Quality target product profiles (QTPPs) of the film-forming system (FFS).
QTPP Target Justification
Route of administration Dermal
Dermal delivery is an opportunity to achieve a high
concentration of the drugs on the application site and to avoid
systemic side effects. Furthermore, it is a non-invasive and
painless administration route, resulting in high
patient compliance.
Dosage form Semisolid in situfilm-forming system
Suitable for dermal and transdermal application, it has a
longer residence time and prevents smearing. Dermatological
treatment may require less frequent dosing of the FFS [7].
Site of activity Deeper layer of the skin The dermal drug delivery system ensures penetration throughthe skin as deep as the therapeutic effects require.
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Table 2. Cont.
QTPP Target Justification
Appearance of semisolid system Transparent or white,homogeneous
To ensure the aesthetic appearance of the film, the semisolid
system has to show similar properties. To increase patient
compliance [7].
Stability
(physical, chemical)
Homogeneous; in the formulation
there is no visible sign
of instability
To ensure applicability, stability is a critical point of
formulation. Appearance change, phase separation, pH
change and viscosity change are stability issues, which can
inhibit usability.
Silicone content Film formation, fast-drying,silky touch
To change the mechanical and drying properties of the film
favorably. Silky on the skin, but neither shiny nor greasy [29].
Packaging material type Well closingAppropriate for the dosage form
The system includes volatile components. The packaging
material type is important to keep these volatile components
in the formulation [15].
Mechanical properties of film for
skin application
Flexible, highly adherent,
resistant film
In order to ensure that the composition achieves the desired
effect, the in situ formed film needs to have suitable
mechanical properties, such as to stay on the skin constantly,
to have flexible movement similar to that of the skin and to be
easily removable in one piece [28].
Table 3. Critical quality attributes (CQAs) of the FFS.
CQA Target Justification
Semisolid System Properties
Physical properties (color, odor,
appearance)
Translucent or white appearance,
homogeneous, clear and odorless smell To increase patient compliance.
Viscosity Optimal spreadability on the skin (range:50,000–150,000 mPas)
Rheological attributes, e.g., viscosity, to influence
the application of the formulation on the skin and
the stability of the semisolid system [28].
Homogeneity Homogenous distribution of thecomponents in the formulation
Homogeneity ensures stability and aesthetic
appearance. During application the uniformity of
dosage units has to be maintained.
pH Optimal pH of transdermal formulation(range: 4–8 pH) For the safety and efficacy of the product.
Skin feeling Not sticky, not greasy, silky touch onthe skin
Formulations containing silicones influence skin
feeling. They are slightly slippery and silky on
the skin. Due to the semi-occlusive effect of
silicones, the skin could be softer and
well-hydrated [29].
Drying time Optimal drying time for comfortable use(within 10 min)
The optimal drying time is a critical point of
comfortable use. The formulation has to dry fast
to avoid smearing [28].
Stability
(physical, chemical)
No visible sign of instability at the time of
preparation and after one month (at room
temperature)
The physical and chemical stability of the
semisolid system is essential to form a
homogeneous, aesthetic appearance, and these
properties ensure the mechanical attributes of the
film for skin application.
Stability (microbiological)
Meets the requirements of the
pharmacopoeia for
dermally-applied systems
The safety of the FFS is a requirement for
marketing authorization.
Film properties
Film appearance Translucent, homogeneous, compact film To increase patient compliance (almost invisible,not shiny, easy to remove) [7].
Film burst strength
Compact film structure approaches the
properties of the heat-separated human
epidermis (range: under 5 N)
The film has to be strong enough to form a
compact film on the skin and not to tear when the
skin is moving.
Skin adhesion
Approach the adhesion of an adhesive
plaster to the skin. (Mean peel range:
100–500 mN)
Good adhesion ensures the residence time on the
skin for the appropriate exposure time.
Film flexibility
Approach the properties of the
heat-separated human epidermis (range:
above 25%)
To follow the skin moving, thereby avoiding the
separation from the skin surface [28].
Film integrity Compact film on the skin surface
To provide aesthetic appearance and easy
removability. It can be pulled down
completely [28].
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3.2. Initial Risk Assessment
Risk assessment refers to the estimate of the risks related to the semisolid in situ FFS containing
silicone. Risk assessment tools can be used to identify and rank parameters (e.g., process, input
materials) with the potential to have an impact upon product quality. After the determination of
QTPPs and CQAs, the following step is to determine critical material attributes (CMAs) and critical
process parameters (CPPs) of the FFS, which are shown in Table 4.
Table 4. Summary of all the parameters that affect the FFS.
QTPPs Impact CQAs CPPs and CMAs Occurrence
Route of administration High Physical properties Mixing rate Medium
Dosage form High Viscosity Mixing time Low
Site of activity Medium Homogeneity Type of mixer Medium
Appearance of semisolid
system Medium pH Temperature of technology High
Stability High Skin feeling Type of technology High
Silicone content High Drying time Viscosity enhancingexcipients Medium
Type of packaging material Medium Stability (physical, chemical) Preservatives Low
Mechanical properties of
film for skin application High Stability (microbiol.) Drying excipients High
Film appearance Film-forming excipients High
Film burst strength Type of silicones High
Skin adhesion
Film flexibility
Film integrity
The risk estimate matrix (REM) includes the connection between the parameters to recognize the
critical quality parameters of the target product [30]. The first REM shows the relationship between
QTPPs and CQAs (Table 5). A three-step scale was used to evaluate the probability relationship
between the parameters: Low (low risk parameters), Medium (medium risk parameters), High (high
risk parameters) were the optional levels. For the probability rating a 1(low)-3(medium)-9 (high) scale
was used. These are the parameters that influence product quality: physical properties (5%), viscosity
and homogeneity (both 6%), pH and skin feeling (both 5%), drying time (9%), physical and chemical
stability (7%), microbiological stability (5%), film appearance (10%), film burst strength, skin adhesion
and film flexibility (both 11%) and film integrity (9%). Based on the results of REM, a Pareto chart
(Figure 2) was created showing the severity scores of the CQAs. The chart draws attention to the
parameters which have a critical effect on quality during the developing process [31].
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Table 5. Risk estimation matrix of QTPP and CQA parameters (LeanQbD™ Software) Low = low risk, Medium = medium risk, High = high risk parameters during
the research work.
CQAs
QTPP Route of
Administration (H)
Dosage Form
(H)
Site of
Activity (M)
Appearance of
Semisolid System (M)
Stability (H) Silicone
Content (H)
Type of Packaging
Material (M)
Mechanical Properties of Film
for Skin Application (H)
Physical
properties 5% Low Low Low High High Medium Medium Low
Viscosity 6% Medium Medium Low Medium Medium Medium Medium High
Homogeneity 6% Low High Low High High Medium Low Low
pH 5% High Medium Medium Low Medium Low Low Low
Skin feeling 5% Medium Medium Low Low Low High Low Medium
Drying time 9% Medium High High Low Medium High Medium High
Stability
(physical,
chemical)
7% Low High Low Medium High Medium Medium Medium
Stability
(microbiol.) 5% Low High Low Medium High Low Low Low
Film
appearance 10% Medium High Low Medium High High Low High
Film burst
strength 11% High High Low Low High High Low High
Skin adhesion 11% High High Medium Low High High Low High
Film flexibility 11% High High Medium Low High High Low High
Film integrity 9% Low High Medium Low High High Low High
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Table 6. Risk estimation matrix of CPPs/CMAs and CQA parameters (LeanQbD™ Software) Low = low risk, Medium = medium risk, High = high risk parameters
during the research work.
CQAs
CMAs, CPPs Mixing Rate (M)
CPP
Mixing Time (L)
CPP
Type of Mixer
(M) CPP
Temperature of
Technology (H) CPP
Type of Technology
(H) CPP
Viscosity Enhancing
Excipients (M) CMA
Preserv-Atives
(L) CMA
Drying Excipients
(H) CMA
Film-Forming
Excipients (H) CMA
Type of Silicones
(H) CMA
Physical
properties 5% High Medium High High High High Low Medium High Medium
Viscosity 6% High Medium Medium High High High Medium Medium Medium Medium
Homogeneity 6% High High High High High High Low Medium High High
pH 5% Low Low Low Low Low High Low Low Low Low
Skin
feeling 5% Low Low Low Low Low Medium Low High High High
Drying
time 9% Low Low Low Low Low Medium Low High Medium High
Stability
(physical,
chemical)
7% High High High High High High Low Medium High High
Stability
(microbiol.) 5% Low Low Low Low Low Low High Low Low Low
Film
appearance 10% Low Low Low Low Medium Medium Low High High High
Film burst
strength 11% Low Low Low Low Low Medium Low High High High
Skin
adhesion 11% Low Low Low Low Low Medium Low High High High
Film
flexibility 11% Low Low Low Low Low Medium Low High High High
Film
integrity 9% Low Low Low Low Low Medium Low High High High
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To sum it up, the FFSs have been planned to ensure the required mechanical properties for dermal
application using QbD tools. This approach allows us to establish the minimum number of experiments
to reduce costs and save time.
The initial risk assessment defined the CMA and CPP parameters to ensure the required CQAs.
Based on the results, the initial risk assessment showed that there were three highly critical material
parameters for CQAs that were the type of silicones, film-forming excipients and drying excipients, and
one medium critical material parameter for CQAs, namely viscosity-enhancing excipients. The process
parameters were not found to be highly critical parameters in this development.
Three CQAs, namely skin adhesion, film flexibility and burst strength, were found to be critical
attributes for the FFS. Furthermore, three CQAs, namely film appearance, film integrity and the drying
time of the semisolid system, were found to be attributes of medium influence. These parameters were
investigated during this research work.
3.3. Skin Adhesion
Skin adhesion studies investigate the force needed to separate the film from the skin surface.
This parameter is very important because good adhesion ensures a longer residence time, but on the
other hand, patients prefer to remove the film without pain, therefore adhesion should be within an
optimum range.
During the experiment, three films were compared with a conventional sticking plaster. The initial
peel and the mean peel forces were measured (Figure 4). The initial peel represents the force to start
pulling off the film, while the mean peeling force is the average of the measured values during the
experiment. Film F1 without silicone (128 mN) and Film F2 with silicones (129 mN) needed nearly as
much force to start pulling off the film as the sticking plaster (105 mN), so they met the requirements of
risk assessment (100–200 mN). In contrast, Film F3 with silicones (61 mN) was easier to start pulling off.
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In the case of the initial peel, the elongation of a film fixed in the upper sample holder of the
instrument resulted in higher adhesion force values compared with the more rigid sticking plaster.
This difference and tendency changed after the initial peel; in the second part of peeling, clear adhesion
force dominated.
Films F1 (157 mN) and F2 (131 mN) also meet the recommended mean peel requirements of the
CQA (100–500 mN). The low value of Film F3 (19 mN) suggests an easy peeling off from the skin, and
thus a short residence time. During the further development of Film F3, an effort should be made to
increase the adhesiveness of the formulation. In summary, the type and the amount of silicones have
remarkable influence on the adhesion of the films to the skin.
3.4. Film Flexibility (Resilience)
One of the most important mechanical properties of films is flexibility, because it can have an
effect on skin feeling, and it can help the formulation to remain on the skin surface. If the film is too
rigid, the movement of the skin surface can induce the development of peeling force, and thus film
separation from the surface. Therefore, during development skin-like flexibility is recommended as a
target value.
During our experiments, the flexibility of three films was compared with each other and with
that of the heat-separated human epidermis. In the CQA an optimal flexibility range (above 25%) was
established. The flexibility of the system was characterized by two parameters: the first is the mean
force at target distance, which shows the resistance of the films during stretching, and the second is the
resilience value. The mean force value at target distance can predict the deformability of the system;
when this force is low, the system is very deformable (minimal force can induce deformation in the
system). The resilience value shows the recovery of the sample from deformation, this parameter can
provide information on product elasticity [32].
As the results show (Figure 5), Film F1 and Film F2 are in the optimal range of resilience values,
which means that these systems can follow and accommodate to the skin movement during the
application. Film F1 (39.1%) has resilience similar to that of the human epidermis (55.2%), and it can be
inferred from the mean force at target distance that this system has more elastic properties. Film F3
(22.9%) has the lowest resilience, which means it has the weakest elasticity.
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3.6. Film Appearance 
The preparations formed translucent, homogeneous, compact films as Figure 7 shows. The film 
was whiter after drying in the case of Film F3. The films containing silicones were softer and not as 
rigid as Film F1. All three films met the requirements, where Films F1 and F2 are optimal if the target 
is long-term translucent usability. 
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3.5. Film Burst Strength
During these measurements, the stiffness of the three films were evaluated and compared with
each other. Burst strength is the force needed to rupture the film, while distance at burst is the
maximum distance of the deformation before the rupture. Film F1 (4.91 N) has the highest film burst
strength, which means that this film is the hardest to break. It is also slightly distensible, Films F2
(1.15 N) and F3 (0.39 N) need lower force to burst, which means that silicones decrease the stiffness of
the films (Figure 6).
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3.6. Film Appearance
The preparations formed translucent, homogeneous, compact films as Figure 7 shows. The film
was whiter after drying in the case of Film F3. The films containing silicones were softer and not as
rigid as Film F1. All three films met the requirements, where Films F1 and F2 are optimal if the target
is long-term translucent usability.
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The preparations formed translucent, homogeneous, compact films as Figure 7 shows. The film 
was whiter after drying in the case of Film F3. The films containing silicones were softer and not as 
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3.7. Film Integrity
All three formulations formed compact films on the skin surface, and the films could be removed
in one piece from the skin (Figure 8). The films met the requirements, but Film F1 was more compact
than films containing silicones.
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As for Film F1, the whole thickness of the film was dry during the drying time. In the case of F3, 
the structure of the film was different; the top of the film was dry in 6 min, but the inner layers stayed 
soft and wet, which can predict better and longer penetration through the skin. 
In order to prove the different drying time and drying mechanism of the FFSs, DSC 
measurements were performed (Mettler-Toledo DSC 821e, Columbus, OH, USA). The evaporation 
mechanism of solvent and volatile components from the FFSs has an effect on the drying of these 
systems and thus on the final characteristics of the films. Figure 10 shows the DSC curves of the 
different FFSs, and the DSC data can be found in Table 7. F1 contains water as its solvent, and ethanol 
as a volatile component. During the examination, one broad endothermic peak appeared on the curve 
(107 °C), which can be identified as the evaporation of water and ethanol simultaneously. In contrast, 
there are two peaks on the curve of F2, where the first peak (at 71 °C) corresponds to the volatile 
silicone (cyclomethicone has a flash point at around 77 °C [33]), while the second peak (at 107 °C) 
indicates the evaporation of water and ethanol together like in the case of F1. Similarly to F2, F3 also 
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3.8. Drying Time of FFSs
The results show (Figure 9) that Film F1 had the longest drying time. The film needed almost
15 min to get dry on the PVA-based artificial skin. In the case of systems containing silicones, drying
time decreased. The drying time of Film F2 was about 10 min. With almost 6 min, the drying attribution
of Film F3 was significantly the fastest.
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As for Film F1, the whole thickness of the film was dry during the drying time. In the case of F3,
the structure of the film was different; the top of the film was dry in 6 min, but the inner layers stayed
soft and wet, which can predict better and longer penetration through the skin.
In order to prove the different drying time and drying mechanism of the FFSs, DSC measurements
were performed (Mettler-Toledo DSC 821e, Columbus, OH, USA). The evaporation mechanism of
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solvent and volatile components from the FFSs has an effect on the drying of these systems and thus
on the final characteristics of the films. Figure 10 shows the DSC curves of the different FFSs, and the
DSC data can be found in Table 7. F1 contains water as its solvent, and ethanol as a volatile component.
During the examination, one broad endothermic peak appeared on the curve (107 ◦C), which can be
identified as the evaporation of water and ethanol simultaneously. In contrast, there are two peaks on
the curve of F2, where the first peak (at 71 ◦C) corresponds to the volatile silicone (cyclomethicone has
a flash point at around 77 ◦C [33]), while the second peak (at 107 ◦C) indicates the evaporation of water
and ethanol together like in the case of F1. Similarly to F2, F3 also shows two peaks during drying, but
the evaporation of the volatile components is not as separated as in the previous case (F2).
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Table 7. DSC data of different FFSs.
FFS Onset (◦C) Peak (◦C) Endset (◦C)
F1 93.71 107.01 140.21
F2
59.16 71.70 80.02
91.57 107.62 113.15
F3
90.67 91.54 93.77
109.34 112.62 120.91
The peak of the evaporated cyclomethicone (at 91.5 ◦C), and that of water and ethanol (at
112.6 ◦C) shifted to higher temperatures and overlapped with each other, which can mean a prolonged
drying time.
When we consider the shape of the curves, it can be clearly seen that the run-off of the endothermic
peak is not so smooth for F2 and F3, which can indicate evaporation hampered by a film layer on the
top of the sample. This hypothesis is in accordance with the visual observation of film drying where a
film layer formed on the top of the sample, while the deeper layers remained wet.
Summarizing the results, the silicone content accelerates drying time and influences the
drying mechanism.
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4. Conclusions
In the present work, dermally applicable, semisolid FFSs containing silicones were developed
with the QbD approach, which forms a film on the skin with the expected mechanical properties.
Based on the results of initial risk assessment, three compositions were formed and investigated.
Initial risk assessment defined the CMAs and the CPPs to ensure the required CQAs. During the
initial risk assessment, three CQAs, namely skin adhesion, film flexibility and burst strength, were
found to be highly critical attributes, and three CQAs, namely film appearance, film integrity and the
drying time of the semisolid system, were found to be medium critical attributes in the development of
FFSs. These parameters were investigated. The initial risk assessment also showed that there are three
material parameters, namely type of silicones, film-forming excipients and drying excipients, which
were highly critical parameters for the CQAs, while viscosity enhancing excipients had a medium
impact on the CQAs.
The texture of FFS films is an important factor during development [34]. The physical properties
of the film highly influence usability, patient compliance and efficacy. In the case of FFSs, the right
burst strength ensures the resistance of the film on the skin surface. Good skin adhesion increases the
residence time and thus the better bioavailability of the drug, but the easy removability of the film is
also important. The resilience value of the system can be a critical factor as well, because if it is similar
to skin flexibility, the system can follow the skin’s movement and provides better skin sensation.
During the experiments, important findings were made (Table 8). The film properties showed
that all three compositions were appropriate regarding appearance and integrity. The films were
translucent and homogenous, and could be removed in one piece. The texture of the films showed
different results. Film F1 had the highest skin adhesion and flexibility (resilient), and the burst strength
showed that this film needed the highest force to burst. Due to the silicone content, softer but less
resistant films were obtained. Film F2 showed closer values to Film F1. As for drying time, Film F3
gave the most promising results because of its different drying mechanism, which can predict higher
drug penetration through the skin in the further development of FFSs-containing drugs.
Table 8. Summary of the investigation of the film formed by FFSs;44: exceptionally good result,4:
The result meets the requirement of Table 3, 6: The result does not meet the requirement of Table 3.
Investigation
Formulation
F1 F2 F3
Skin adhesion 4 4 6
Film flexibility 4 4 6
Film burst strength 4 4 4
Film appearance 4 4 4
Film integrity 4 4 4
Drying time 6 4 44
In summary, silicone content has a great effect upon the properties of the films. Different silicones
affect the mechanical properties of films in different ways. Non-volatile silicones soften the films,
thereby decreasing the mechanical attributes, while volatile silicone helps to form films and accelerate
drying. Based on these results, the proper FFS-containing silicone could be chosen, which can function
as an applicable drug delivery system in the case of any development of FFS containing different APIs.
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